BYOMass Inc. is a preclinical metabolic disease biotech structured around development of therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses. In metabolic disease space, the focus / target is primarily on tissues - liver, muscle and pancreas. BYOmass principals indicate their focus will instead be focusing on how the brain controls metabolism - "more specifically ,how the hypothalamus and the brain stem performâ¦to help maintain food intake, body weight and blood pressure.
